Chardan Capital Lowers Tocagen (NASDAQ:TOCA) to Neutral
Chardan Capital lowered shares of Tocagen (NASDAQ:TOCA) from a buy rating to a neutral rating in a research report released on Friday, BenzingaRatingsTable reports. Chardan Capital currently has $1.00 price target on the stock.
A number of other analysts have also recently weighed in on the stock. Zacks Investment Research raised shares of Tocagen from a hold rating to a buy rating and set a $4.25 price objective on the stock in a report on Thursday, September 12th. Citigroup initiated coverage on shares of Tocagen in a report on Thursday, May 30th. They set a buy rating on the stock. Leerink Swann set a $5.00 price objective on shares of Tocagen and gave the stock a hold rating in a report on Wednesday, May 22nd. B. Riley cut shares of Tocagen from a buy rating to a neutral rating in a report on Thursday, September 12th. Finally, Cantor Fitzgerald cut shares of Tocagen from an overweight rating to a neutral rating in a report on Thursday, September 12th. Ten equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $10.62.
TOCA stock opened at $0.95 on Friday. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.86. Tocagen has a twelve month low of $0.73 and a twelve month high of $15.80. The company’s 50 day moving average is $4.00 and its two-hundred day moving average is $7.08. The stock has a market cap of $22.60 million, a P/E ratio of -0.39 and a beta of 4.07.
Several institutional investors have recently made changes to their positions in TOCA. Sphera Funds Management LTD. acquired a new position in shares of Tocagen in the 1st quarter valued at $1,304,000. Rubric Capital Management LP acquired a new position in shares of Tocagen in the 1st quarter valued at $1,176,000. GSA Capital Partners LLP acquired a new position in shares of Tocagen in the 2nd quarter valued at $551,000. JPMorgan Chase & Co. increased its holdings in shares of Tocagen by 19.0% in the 1st quarter. JPMorgan Chase & Co. now owns 453,391 shares of the company’s stock valued at $4,929,000 after acquiring an additional 72,539 shares during the period. Finally, LPL Financial LLC acquired a new position in shares of Tocagen in the 2nd quarter valued at $384,000. 35.38% of the stock is currently owned by institutional investors and hedge funds.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Featured Article: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.